Cellebrite DI [CLBT] vs Oracle [ORCL] Detailed Stock Comparison

Cellebrite DI

NASDAQ
Loading...

Oracle

NYSE
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: Cellebrite DI wins in 7 metrics, Oracle wins in 12 metrics, with 0 ties. Oracle appears stronger overall.

View Metrics Details

Vital Metrics Comparison

MetricCellebrite DIOracleBetter
P/E Ratio (TTM)69.0966.08Oracle
Price-to-Book Ratio11.1433.66Cellebrite DI
Debt-to-Equity Ratio5.47452.53Cellebrite DI
PEG Ratio46.55-35.02Oracle
EV/EBITDA55.0437.37Oracle
Profit Margin (TTM)-34.56%21.08%Oracle
Operating Margin (TTM)14.58%31.38%Oracle
EBITDA Margin (TTM)14.58%31.38%Oracle
Return on Equity-81.98%69.24%Oracle
Return on Assets (TTM)5.95%7.15%Oracle
Free Cash Flow (TTM)$121.56M$-394.00MCellebrite DI
Dividend YieldN/A0.81%N/A
1-Year Return2.38%61.71%Oracle
Price-to-Sales Ratio (TTM)10.4213.82Cellebrite DI
Enterprise Value$4.10B$914.26BOracle
EV/Revenue Ratio9.3915.49Cellebrite DI
Gross Profit Margin (TTM)84.39%67.28%Cellebrite DI
Revenue per Share (TTM)$2$21Oracle
Earnings per Share (Diluted)$-0.72$4.33Oracle
Beta (Stock Volatility)1.301.53Cellebrite DI
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends

Cellebrite DI vs Oracle Stock Performance Analysis

Loading Price Chart...

Cellebrite DI
Oracle
Cellebrite DI Stock Overview | Oracle Stock Overview

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Cellebrite DI-1.62%-0.22%8.19%21.25%3.07%-14.64%
Oracle-2.52%1.07%19.19%22.38%123.53%71.20%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Cellebrite DI2.38%333.02%91.41%91.41%91.41%91.41%
Oracle61.71%341.98%371.45%660.61%883.53%2,209.02%

News Based Sentiment: Cellebrite DI vs Oracle

Cellebrite DI

News based Sentiment: MIXED

The month of October 2025 presented a mixed picture for Cellebrite, with positive analyst upgrades and a 'Conviction List' inclusion offset by some institutional selling and tempered price target revisions. The upcoming Q1 2024 earnings release on May 9, 2024, will be a key catalyst for investors to assess the company's performance and future prospects, particularly in light of its focus on AI and potential benefits from federal spending.

View Cellebrite DI News Sentiment Analysis

Oracle

News based Sentiment: MIXED

October was a pivotal month for Oracle, marked by a massive surge in RPO driven by the OpenAI partnership, but also overshadowed by concerns about rising debt, high valuation, and insider selling. The mixed analyst reactions and regulatory scrutiny add to the complexity, making it a significant month for investors to reassess the risk-reward profile.

View Oracle News Sentiment Analysis

Performance & Financial Health Analysis: Cellebrite DI vs Oracle

MetricCLBTORCL
Market Information
Market Cap i$4.67B$819.55B
Market Cap CategoryMid capMega cap
10 Day Avg. Volume i1,491,44028,166,510
90 Day Avg. Volume i1,759,98029,452,477
Last Close$18.49$284.24
52 Week Range$13.10 - $26.30$118.86 - $345.72
% from 52W High-29.70%-17.78%
All-Time High$26.30 (Feb 03, 2025)$345.72 (Sep 10, 2025)
% from All-Time High-29.70%-17.78%
Growth Metrics
Quarterly Revenue Growth0.18%0.12%
Quarterly Earnings Growth0.18%0.00%
Financial Health
Profit Margin (TTM) i-0.35%0.21%
Operating Margin (TTM) i0.15%0.31%
Return on Equity (TTM) i-0.82%0.69%
Debt to Equity (MRQ) i5.47452.53
Cash & Liquidity
Book Value per Share (MRQ)$1.67$8.50
Cash per Share (MRQ)$1.93$3.87
Operating Cash Flow (TTM) i$161.08M$21.53B
Levered Free Cash Flow (TTM) i$122.92M$-2,832,250,112
Dividends
Last 12-Month Dividend Yield iN/A0.81%
Last 12-Month Dividend iN/A$1.70

Valuation & Enterprise Metrics Analysis: Cellebrite DI vs Oracle

MetricCLBTORCL
Price Ratios
P/E Ratio (TTM) i69.0966.08
Forward P/E i46.5539.96
PEG Ratio i46.55-35.02
Price to Sales (TTM) i10.4213.82
Price to Book (MRQ) i11.1433.66
Market Capitalization
Market Capitalization i$4.67B$819.55B
Enterprise Value i$4.10B$914.26B
Enterprise Value Metrics
Enterprise to Revenue i9.3915.49
Enterprise to EBITDA i55.0437.37
Risk & Other Metrics
Beta i1.301.53
Book Value per Share (MRQ) i$1.67$8.50

Financial Statements Comparison: Cellebrite DI vs Oracle

Financial Metrics

Loading Financial Charts...

Revenue

EBITDA

Shareholders Equity

Operating Margin

Free Cash Flow

Long Term Debt

Profit Margin

Current Ratio

Operating Cash Flow

Income Statement (MRQ)

Metric (MRQ)CLBTORCL
Revenue/Sales i$113.28M$15.90B
Cost of Goods Sold i$17.68M$4.74B
Gross Profit i$95.60M$11.16B
Research & Development i$28.61M$2.65B
Operating Income (EBIT) i$14.42M$5.19B
EBITDA i$17.01M$7.00B
Pre-Tax Income i$20.79M$4.15B
Income Tax i$1.32M$725.00M
Net Income (Profit) i$19.48M$3.43B

Balance Sheet & Liquidity Metrics (MRQ)

Metric (MRQ)CLBTORCL
Cash & Equivalents i$90.48M$10.79B
Total Current Assets i$523.48M$24.58B
Total Current Liabilities i$287.80M$32.64B
Long-Term Debt i$6.39M$96.83B
Total Shareholders Equity i$363.49M$20.97B
Retained Earnings i$-147.46M$-15.48B
Property, Plant & Equipment i$28.03M$0

Cash Flow Statement Comparison (MRQ)

Metric (MRQ)CLBTORCL
Operating Cash Flow i$28.07M$5.93B
Capital Expenditures i$-2.34MN/A
Free Cash Flow i$18.54M$-2.92B
Debt Repayment iN/A$-6.07B
Common Stock Repurchase iN/A$-150.00M

Short Interest & Institutional Ownership Analysis

MetricCLBTORCL
Shares Short i8.02M23.58M
Short Ratio i3.580.97
Short % of Float i0.07%0.01%
Average Daily Volume (10 Day) i1,491,44028,166,510
Average Daily Volume (90 Day) i1,759,98029,452,477
Shares Outstanding i234.52M2.81B
Float Shares i112.43M1.67B
% Held by Insiders i0.43%0.41%
% Held by Institutions i0.50%0.45%

Dividend Analysis & Yield Comparison: Cellebrite DI vs Oracle

MetricCLBTORCL
Last 12-Month Dividend iN/A$1.70
Last 12-Month Dividend Yield iN/A0.81%
3-Year Avg Annual Dividend iN/A$1.55
3-Year Avg Dividend Yield iN/A0.36%
3-Year Total Dividends iN/A$4.66
Ex-Dividend DateN/AApr 10, 2025